News

Hypha’s Q3 2017 newsletter: Off-target activity of drug metabolites

This quarter we look at interesting off-target activity of some drug metabolites, using the metabolism of valsartan to 4-hydroxyvaleryl-valsartan as a case study.

Click here for a pdf of the newsletter.

More News

Q2 2026 – PROTAC MetID focus

Q2 2026 newsletter – PROTAC MetID focus From tackling the metabolism of PROTACs to synthesising oxidised metabolites, our latest newsletter features a MetID study undertaken

Welcome to Iain Beattie

Welcome to Iain Beattie We’re delighted to welcome Iain Beattie to Hypha as Scientific Fellow in Biotransformation and MetID. Iain brings a wealth of expertise

Q1 2026 – LC-MS/MS MetID Service

Q1 2026 Newsletter – LC/MS-MS MetID Service Hypha provides a high quality LC-MS/MS based MetID Service to complement our existing definitive MetID capabilities using NMR

Ready to begin? Our scientists are available to talk through your requirements

Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.

News

Hypha’s Q3 2017 newsletter: Off-target activity of drug metabolites

More News

Q2 2026 – PROTAC MetID focus

Welcome to Iain Beattie

Q1 2026 – LC-MS/MS MetID Service

Ready to begin? Our scientists are available to talk through your requirements

What We Do

Our Products

Our Science

Resources

Don't forget to subscribe to our newsletter and blog!